The nomination committee’s proposal of board of directors in ADDvise Group AB (publ) - Regulatory information

23-02-2021   Regulatory press release

To the annual general Meeting (AGM) of ADDvise Group AB (publ) on 23 April 2021, the nomination committee has decided to propose the re-election of the current board members Rikard Akhtarzand, Fredrik Celsing, Staffan Torstensson and Erland Pontusson as members of the board of directors. In addition, the nomination committee proposes the election of Johanne Louise Brændgaard. It is proposed that Staffan Torstensson is re-elected chairman of the board of directors.

Johanne Louise Brændgaard has a master’s degree in international business economics from Aalborg University, Denmark. Johanne Louise Brændgaard has extensive experience in global sales, marketing and project managing within the MedTech industry from positions at Cook Medical and Getinge. Johanne Louise Brændgaard is independent in relation to the company, its management, and its largest shareholders.

A presentation of the current members of the board of directors is available on ADDvise Group’s website.

The nomination committee's full proposals to the AGM 2021 will be published in connection with the notice to the AGM 2021.

The nomination committee of ADDvise Group for the AGM 2021 consists of Per-Anders Tammerlöv (chairman of the nomination committee) appointed by Rikard Akhtarzand, shareholder through direct and indirect ownership, Per Åhlgren, shareholder through indirect ownership, Magnus Vahlquist, shareholder through direct and indirect ownership and Staffan Torstensson, chairman of ADDvise Group AB. The members of the nomination committee jointly represent approximately 47 per cent of the votes in the company.  

For further information, please contact:

Rikard Akhtarzand, CEO
+46 765-25 90 71
rikard.akhtarzand@addvisegroup.se

About ADDvise Group

ADDvise Group AB (publ) is a leading supplier of equipment to healthcare and research facilities. The group consists of approximately 10 subsidiaries organized into two business areas, Lab and Healthcare. Sales are global. The Group has a clear acquisition strategy with the aim of raising shareholder value and expand the business – both geographically and product wise. ADDvise Group’s shares are listed on Nasdaq First North Growth Market and Mangold Fondkommission AB, +46 8 503 015 50, CA@mangold.se, is the Company's Certified Adviser. Additional information is available at www.addvisegroup.com.

    

Latest press releases

Interim report 2025, January 1–June 30

Regulatory

In the second quarter of 2025, organic sales adjusted for currency effects increased, driven by steady demand for laboratory equipment and rental of equipment for clinical studies. Operating cash flow improved in the quarter, and EBITA was in line with last year with a stronger margin. Through the new capital structure, ADDvise’s annual interest expenses…

Invitation to presentation of interim report April 1 – June 30, 2025

Non-regulatory

ADDvise Group publishes its interim report April 1 – June 30, 2025 on Thursday, July 17, 2025 at 7.45 am (CET). Media, investors and analysts are invited to attend a webcast and teleconference on the same day at 14:00 (CET). CEO, Staffan Torstensson, and CFO, Johan Irwe, will present the report. Webcast If you wish to…

ADDvise announces that the conditions for early redemption of outstanding secured bonds have been fulfilled

Regulatory

ADDvise Group AB (publ) (“ADDvise” or the “Company”) announced on 14 May 2025 that ADDvise intends to redeem the Company’s outstanding senior secured bonds with ISIN SE0020180271 and ISIN NO0013180786 (the “Early Redemption”). The Early Redemption was conditional upon the entering into of the new secured facilities agreement of the equivalence of SEK 450 million…